Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation

Transplant Infectious Disease

Volumn 14, Issue 1, 2012, Pages 33-39

  Ishiyama, K ^a,b   Katagiri, T ^a   Ohata, K ^a   Hosokawa, K ^a   Kondo, Y ^a   Yamazaki, H ^a   Takami, A ^c   Nakao, S ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Foscarnet sodium; Hematopoietic stem cell transplantation; Human herpesvirus 6; Limbic encephalitis

Indexed keywords

FOSCARNET; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CYSTITIS; DEATH; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; HEPATOBILIARY DISEASE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 6 ENCEPHALITIS; HYPOALBUMINEMIA; INFECTION; INFECTION PREVENTION; KIDNEY DISEASE; MALE; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; UMBILICAL CORD BLOOD; UNSPECIFIED SIDE EFFECT; VIRUS ENCEPHALITIS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; ENCEPHALITIS, VIRAL; FEMALE; FOSCARNET; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 6, HUMAN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ROSEOLOVIRUS INFECTIONS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 84857042281     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00662.x     Document Type: Article

References (15)

1. Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(3): 309-317.
2. Fujimaki K, Mori T, Kida A, et al. Human herpesvirus 6 meningoencephalitis in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2006; 84(5): 432-437.
3. Wang H, Zhu L, Xue M, Liu J, Guo Z. Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(4): 519-520.
4. Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant 2011; 46(6): 863-869.
5. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37(1): 132-136.
6. Tanaka N, Kimura H, Hoshino Y, et al. Monitoring four herpesviruses in unrelated cord blood transplantation. Bone Marrow Transplant 2000; 26(11): 1193-1197.
7. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol 2001; 11(6): 381-395.
8. De Clercq E, Naesens L. In search of effective anti-HHV-6 agents. J Clin Virol 2006; 37(Suppl 1): S82-86.
9. Pohlmann C, Schetelig J, Reuner U, et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipient. Clin Infect Dis 2007; 44(12): e118-120.
10. Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49(3): 306-312.
11. Narimatsu H, Kami M, Kato D, et al. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation. Transpl Infect Dis 2007; 9(1): 11-15.
12. Rapaport D, Engelhard D, Tagger G, Or R, Frenkel N. Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients. Transpl Infect Dis 2002; 4(1): 10-16.
13. Tokimasa S, Hara J, Osugi Y, et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29(7): 595-598.
14. Ogata M, Satou T, Kawano R, et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008; 41(3): 279-285.
15. Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006; 193(1): 68-79.